Market Overview

UPDATE: Canaccord Genuity Reiterates Buy Rating, Raises PT on Aegerion Pharmaceuticals

Related AEGR
Aegerion Pharmaceuticals Appoints Gregory Perry as CFO
Aegerion Pharmaceuticals Announces Key Additions to Medical Affairs and Drug Safety

In a report published Wednesday, Canaccord Genuity reiterated its Buy rating on Aegerion Pharmaceuticals (NASDAQ: AEGR), and raised its price target from $27.00 to $36.00.

Canaccord Genuity noted, “AEGR announced additional Juxtapid launch color, with the key takeaways being the $235K/$295K U.S. annual pricing (vs. our $250K estimate) for initiation/maintenance, respectively, and that >1,500 patients have been identified worldwide to date through the registry. As a result, we believe AEGR's goal of 250-300 patients on drug by YE13 and $15M - $25M FY13 revenue guidance (we model for $22M) could prove conservative. We have adjusted our model to account for the higher pricing and a slower 2013 ramp but increased revenue in 2014+.”

Aegerion Pharmaceuticals closed on Tuesday at $25.76.

Latest Ratings for AEGR

Oct 2014JefferiesDowngradesBuyHold
Oct 2014JP MorganDowngradesOverweightNeutral
Oct 2014Deutsche BankDowngradesBuyHold

View More Analyst Ratings for AEGR
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Price Target Analyst Ratings


Related Articles (AEGR)

Around the Web, We're Loving...

Get Benzinga's Newsletters